
Silexion Therapeutics (SLXN)
NasdaqMarket Closed
Silexion Therapeutics Corp is a clinical-stage biotechnology company developing oncology treatments for cancers associated with KRAS mutations. KRAS is one of the most frequently altered oncogenes in human cancer and has historically been difficult to target, making it an important area of research across pancreatic, colorectal, lung, and other solid tumour indications.
The company’s approach is based on RNA interference, using small interfering RNA, or siRNA, constructs intended to reduce production of mutant KRAS proteins. Rather than inhibiting a protein after it is made, Silexion’s technology is designed to interfere earlier in the disease pathway by prompting degradation of the messenger RNA that carries instructions from the mutated gene to the cell’s protein-making machinery. This mechanism is intended to limit the cancer-driving effects of KRAS mutations at the molecular level.
Silexion’s lead candidate, SIL204, is described as a second-generation siRNA therapy engineered to suppress mutated KRAS protein production. The company’s siRNA constructs are chemically modified with the aim of improving stability and cellular uptake while preserving biological activity. These properties are important for RNA-based medicines because delivery, durability, and target engagement can strongly influence therapeutic potential.
As an oncology-focused clinical-stage company, Silexion’s prospects depend on the progression of its research and clinical programmes, the strength of its intellectual property, access to capital, and evidence that its platform can translate into meaningful patient benefit. Its focus on KRAS places it in a competitive but medically significant field where new treatment options remain in demand.
Last updated
- Market Cap
- $2,073,078
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- —
- Sector
- Materials
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 12 ABBA HILLEL ROAD, RAMAT GAN, L3, 5250606
Silexion Therapeutics Announces Initiation of GMP Clinical Supply Manufacturing of SIL204 with Leading Global CDMO, and New Approval of Phase 2/3 Trial From Tel Aviv Sourasky Medical Center
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $2,073,078
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- —
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- —
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- —
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- —
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- —
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- —
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- —
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- —
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- —
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- —
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- —
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- —
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- —
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- —
Financial statements are not available for this listing.
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| edgar index | S-1/A — Silexion Therapeutics Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | S-1 — Silexion Therapeutics Corp | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEFA14A — Silexion Therapeutics Corp | View Filing | |
| edgar index | SCHEDULE 13D/A — Silexion Therapeutics Corp | View Filing | |
| edgar index | 424B3 — Silexion Therapeutics Corp | View Filing | |
| edgar index | EFFECT — Silexion Therapeutics Corp | View Filing | |
| edgar index | DEF 14A — Silexion Therapeutics Corp | View Filing | |
| edgar index | S-3 — Silexion Therapeutics Corp | View Filing | |
| edgar index | 4 — Silexion Therapeutics Corp | View Filing | |
| edgar index | 4 — Silexion Therapeutics Corp | View Filing | |
| edgar index | 4 — Silexion Therapeutics Corp | View Filing | |
| form 4 | Form 4 — Hadar Ilan | View Filing | |
| form 4 | Form 4 — Hadar Ilan | View Filing | |
| form 4 | Form 4 — Horenshtein Hadar Mirit | View Filing | |
| form 4 | Form 4 — Shirvan Mitchell | View Filing | |
| form 4 | Form 4 — Shirvan Mitchell | View Filing | |
| edgar index | PRE 14A — Silexion Therapeutics Corp | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| edgar index | SCHEDULE 13D/A — Silexion Therapeutics Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | S-8 — Silexion Therapeutics Corp | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 10-K/A — Silexion Therapeutics Corp | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — Silexion Therapeutics Corp | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| edgar index | 10-Q — Silexion Therapeutics Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| edgar index | EFFECT — Silexion Therapeutics Corp | View Filing | |
| edgar index | EFFECT — Silexion Therapeutics Corp | View Filing | |
| edgar index | POS AM — Silexion Therapeutics Corp | View Filing | |
| edgar index | POS AM — Silexion Therapeutics Corp | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| edgar index | DEFA14A — Silexion Therapeutics Corp | View Filing | |
| edgar index | DEF 14A — Silexion Therapeutics Corp | View Filing | |
| edgar index | 4 — Silexion Therapeutics Corp | View Filing | |
| edgar index | PRE 14A — Silexion Therapeutics Corp | View Filing | |
| form 4 | Form 4 — Shirvan Mitchell | View Filing | |
| form 4 | Form 4 — Shirvan Mitchell | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| edgar index | 8-K — Silexion Therapeutics Corp | View Filing | |
| edgar index | 10-K — Silexion Therapeutics Corp | View Filing | |
| edgar index | DRS — Silexion Therapeutics Corp | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | DEFA14A — Silexion Therapeutics Corp | View Filing | |
| edgar index | 4 — Silexion Therapeutics Corp | View Filing | |
| edgar index | DEF 14A — Silexion Therapeutics Corp | View Filing | |
| edgar index | 4 — Silexion Therapeutics Corp | View Filing | |
| edgar index | 4 — Silexion Therapeutics Corp | View Filing | |
| edgar index | 4 — Silexion Therapeutics Corp | View Filing | |
| edgar index | 4 — Silexion Therapeutics Corp | View Filing | |
| edgar index | 4 — Silexion Therapeutics Corp | View Filing | |
| edgar index | 4 — Silexion Therapeutics Corp | View Filing | |
| edgar index | 4 — Silexion Therapeutics Corp | View Filing | |
| form 4 | Form 4 — Lushi Avner | View Filing |